Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Baptist Health South Florida, Miami Cancer Institute in Florida turned to technology to provide high-quality cancer care without having to dip deeper into its operating budget.
Rockville, MD—August 23, 2022 - The Association of Community Cancer Centers (ACCC) announced today that Baptist Health’s Miami Cancer Institute a recipient of a 2022 ACCC Innovator Award. The award recognizes Miami Cancer Institute’s use of technology to improve patient oral oncolytic consent compliance. It’s common for cancer programs and practices to struggle with timely treatment education, consent …
CORP-US3817 EAP Journal Ad copy R7 copy • Benefits investigation • Financial assistance • Appeal Information• Eisai Assistance Program Hotline • Prior Authorization Information © 2022 Eisai Inc. All rights reserved. CORP-US3817 June 2022 At Eisai, everything we do is guided by a simple principle: patients and their families come first and we have a responsibility to …
By turning to technology solutions that are already being used by the health system and that were well understood by their healthcare teams and patients, Baptist Health South Florida, Miami Cancer Institute staff are providing high-quality cancer care without having to dip deeper into its operating budget.
JA08-Tools
Rockville, MD—The Association of Community Cancer Centers (ACCC) announced today that Virginia Commonwealth University (VCU) Health System, VCU Massey Cancer Center in Richmond, Va., is a recipient of a 2022 ACCC Innovator Award. This award recognizes VCU Health System’s medical-legal partnership, which is addressing social determinants of health that have a remedy in civil law. Through a collaboration …
Teri Bedard, RT(R)(T), CPC, shares her highlights of the calendar year 2023 HOPPS proposed rule and its potential impact on oncology/hematology.
Around half of patients with cancer and survivors of cancer are dealing with financial toxicity, and one of the best ways to handle this is through financial navigation. For 18 years, the Patient Access Network (PAN) Foundation has helped patients pay their out-of-pocket treatment costs.
Teri Bedard, RT(R)(T), CPC, shares her highlights of the calendar year 2023 MPFS proposed rule and its potential impact on oncology/hematology.
ASSOCIATION OF COMMUNITY CANCER CENTERS ONCOLOGIC INTRAVENOUS AND ORAL COMBINATION REGIMENS STRATEGIES FOR CARE COORDINATION Effective Practices Publication TABLE OF CONTENTS Introduction .....................................................................................................2 Top Challenges …
TENNESSEE ONCOLOGY PRACTICE SOCIETY (TOPS) MEMBERS ENJOY A 50% DISCOUNT WHEN REGISTERING ONLINE REGISTER TODAY! USE DISCOUNT CODE DURING REGISTRATION: TOPS50 info@meccinc.com | 305.663.1628 | meccinc.com
Rockville, MD—The Association of Community Cancer Centers (ACCC) announced today that Ochsner Cancer Institute in New Orleans, La., is a recipient of a 2022 ACCC Innovator Award. The award recognizes Ochsner Cancer Institute’s Chemotherapy Care Companion program—a digital technology system that allows the cancer care team to remotely monitor patients who are on intravenous or oral anti-cancer treatment …
Since implementation, Chemotherapy Care Companion has decreased patients’ healthcare costs by preventing emergency department (ED) visits and hospitalizations and improved their overall satisfaction.
iNNOVATiON DECONSTRUCTING SPONSORSHIP & EXHIBIT PROSPECTUS ACCC n n n n n Palm Beach Palm Beach Convention CenterConvention Center October 12–14, 2022 39TH NATIONAL ONCOLOGY CONFERENCE ONCOLOGY CONFERENCE The ASSOCIATION OF COMMUNITY CANCER CENTERS (ACCC) invites you to become a sponsor for its 39th National Oncology Conference, October 12–14, 2022, at the Palm …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Xalkori® (crizotinib) – Pfizer received approval to market its kinase inhibitor for the treatment of adult and pediatric patients with ALK-positive unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, a rare soft-tissue malignancy. The approval was …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Xalkori® (crizotinib) – Pfizer received approval to market its kinase inhibitor for the treatment of adult and pediatric patients with ALK-positive unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, a rare soft-tissue malignancy. The approval was …
Hear how malnutrition affects people with cancer in different ways, even impacting cancer treatment plans.
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Xalkori® (crizotinib) – Pfizer received approval to market its kinase inhibitor for the treatment of adult and pediatric patients with ALK-positive unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, a rare soft-tissue malignancy. The approval was …
Accelerated Approvals Reconsidered None Changes in Dosing/Administration None Changes in Labeled Indications Xalkori® (crizotinib) – Pfizer received approval to market its kinase inhibitor for the treatment of adult and pediatric patients with ALK-positive unresectable, recurrent, or refractory inflammatory myofibroblastic tumor, a rare soft-tissue malignancy. The approval was …